SPONSORS
 |
Our mission is to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. The RPx platform is intended to ignite a local and systemic response to cancer. We imagine a world where cancer is a curable disease. |
 |
Sun Pharma is a global Pharmaceutical company with its Western European Headquarters based near Amsterdam (The Netherlands).
Sun Pharma dedicates significant investments to innovative drugs, addressing high unmet clinical needs in Dermato-Oncology. |
SUPPORTER
|
SkylineDx is a biotechnology company focused on research and development of molecular diagnostics in dermatology, hematology, and inflammatory diseases. SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predicting a patient’s response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. SkylineDx is headquartered in the Netherlands, complemented by a US base of operations and a CAP/CLIA certified laboratory in San Diego California, USA. |
EXHIBITOR
|
Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. We aim to transform disease management by keeping patients and clinicians first. Our innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions provide personalized, clinically actionable information to clinicians and patients to guide treatment decisions and improve health outcomes. |
 |
The Crotts Global Initiative for Extramammary Paget’s Disease at Emory University is a collaborative research initiative dedicated to advancing understanding and treatment of Extramammary Paget’s Disease (EMPD). Through a centralized biobank, patient registry, and growing international partnerships, we aim to accelerate discovery and improve outcomes for EMPD patients worldwide. Our program welcomes collaboration with clinicians, researchers, and institutions committed to expanding knowledge and developing evidence-based approaches for this rare disease. |